Emetend 150 Mg 150 mg Powder for solution for infusion
PDF Leaflet Revision Date: 20 September 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy.
Dosage (summary)
150 mg IV infusion over 20-30 mins on Day 1, 30 mins prior to chemotherapy.
Onset of Action / Duration
Onset: 30 mins, Duration: Not specified.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; breastfeeding not advised.
Key Drug Interactions
- CYP3A4 inhibitors
- Warfarin
- Hormonal contraceptives
Contraindications
- Hypersensitivity to aprepitant
- Co-administration with pimozide or cisapride
Common side effects
- Hiccups
- Fatigue
- Headache
- Dyspepsia
Counselling Points
- Administer IV only, not as bolus
- Monitor INR if on warfarin
- Use non-hormonal contraception during treatment
Serious warnings
- Hypersensitivity reactions
- Use with caution in hepatic impairment
Important Disclaimer
The Emetend 150 Mg 150 mg Powder for solution for infusion professional information leaflet below is the property of Accord Healthcare and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
